Keytruda® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) – Expanded indication, accelerated approval converted to full approval

- On December 15, 2023, Astellas/Pfizer and Merck announced the full FDA approval of Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).
    - This combination regimen was previously approved via accelerated approval for locally advanced or mUC who are not eligible to receive cisplatin-containing chemotherapy. This full approval expands the labeled indication to include patients who are eligible to receive cisplatin chemotherapy.
- Refer to the Padcev and Keytruda drug labels for a complete listing of both of their other uses and indications.
- The approval of Padcev plus Keytruda for the expanded indication and full approval was based on EV-302 (also known as KEYNOTE-A39), an open-label, randomized study in 886 patients with locally advanced or mUC who received no prior systemic therapy for locally advanced or metastatic disease. Patients were randomized to receive either Padcev plus Keytruda or chemotherapy (gemcitabine with cisplatin or carboplatin). The major outcome measures were overall survival (OS) and progression-free survival (PFS). An additional outcome measure was objective response rate (ORR).
    - Median OS was 31.5 months vs. 16.1 months for Padcev plus Keytruda vs. chemotherapy, respectively (hazard ratio [HR] 0.47, 95% CI: 0.38, 0.58; $p < 0.0001$).
    - Median PFS was 12.5 months vs. 6.3 months for Padcev plus Keytruda vs. chemotherapy, respectively (HR 0.45, 95% CI: 0.38, 0.54; $p < 0.0001$).
    - The ORR was 67.7% (95% CI: 63.1, 72.1) vs. 44.4% (95% CI: 39.7, 49.2) for Padcev plus Keytruda vs. chemotherapy, respectively ($p < 0.0001$).
- Padcev carries a boxed warning for serious skin reactions.
- When given in combination with Keytruda for locally advanced or mUC, the recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥ 100 kg) administered as an intravenous (IV) infusion on days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity.
- When given in combination with Padcev for locally advanced or mUC, the recommended dose of Keytruda is 200 mg every 3 weeks or 400 mg every 6 weeks administered as an IV infusion until disease progression, unacceptable toxicity, or up to 24 months. Keytruda should be administered after Padcev when given on the same day.
- Refer to the Padcev and Keytruda drug labels for dosing and administration recommendations for their other uses and indications.